Kajian klinikal Leukemia di Colorado
15 kajian untuk Leukemia sedang mencari peserta di lokasi di Colorado.
Bandar di Colorado
Teks kajian rasmi (Bahasa Inggeris)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
Mengambil pesertaKajian pemerhatian
Umur 0 hingga 38 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06131801A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Colorado, Aurora
Mengambil pesertaFasa 1/2
30 Days · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04065399Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Denver
Mengambil pesertaFasa 3
Umur 18 hingga 18 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07509151First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
- Children's Hospital Colorado, Aurora
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Sep 2026 · NCT07586618Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Colorado Blood Cancer Institute, Denver
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT06001788Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Colorado Children's Hospital, Denver
Mengambil pesertaFasa 2
Umur 7 hingga 25 · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Colorado Blood Cancer Institute, Denver
Mengambil pesertaFasa 1/2
Umur 13 hingga 90 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06533579Integrated Cancer Repository for Cancer Research
- Advent Health, Greenwood Village
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699Shwachman Diamond Syndrome Registry and Study
- Children's Hospital Colorado, Aurora
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 6 Apr 2026 · NCT06056908A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Mac 2026 · NCT05735184Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families
- Children's Hospital Colorado, Aurora
Mengambil pesertaKajian pemerhatian
Sehingga umur 22 · Semua jantina · Dikemas kini 5 Feb 2026 · NCT05425992Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
- University of Colorado Hospital, Aurora
Mengambil pesertaFasa 1
Umur 18 hingga 80 · Semua jantina · Dikemas kini 15 Jan 2026 · NCT06429449Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Rocky Mountain Cancer Centers, Aurora
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Okt 2025 · NCT06549790SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Aurora
- Massive Bio SYNERGY-AI site, Denver
- Massive Bio SYNERGY-AI site, Littleton
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.